The impact of habitual dietary protein intake on the anabolic response in elderly men

The impact of habitual dietary protein intake on the anabolic response in elderly men - Pro-Hab study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON38469

Enrollment

Registered

2013-12-04

Start date

2014-01-24

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related muscle loss sarcopenia

Interventions

Subjects will receive food bags for 14 days, containing either a low (0.7 g/kg BW/d) or high (1.5 g/kg BW/d) protein diet. Following this (i.e. day 15), the subjects will report to the laboratory in

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Healthy males * Age between 55 and 75 y * BMI between 18.5 and 30 kg/m2

Exclusion criteria

Exclusion criteria: * Lactose intolerance * Smoking and alcohol abuse * Diabetes * Diagnosed GI tract diseases * Arthritic conditions * A history of neuromuscular problems * Any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications). * Use of anticoagulants * Participation in exercise program * Hypertension, high blood pressure that is above 140/90 mmHg.

Design outcomes

Primary

Measure	Time frame
The main study endpoint is muscle protein synthesis (MPS) rates. In order to determine the MPS, the following parameters will be measured: * Muscle protein-bound L-[D5]-phenylalanine enrichment (expressed as MPE) * Muscle free (intracellular) L-[D5]-phenylalanine enrichment (expressed as MPE) * Plasma L-[D5]-phenylalanine enrichment (expressed as MPE)	—

Secondary

Measure	Time frame
Secondary endpoints include protein digestion and amino acid absorption kinetics and whole-body protein synthesis, breakdown, oxidation, and net balance. Therefore, the following parameters will be measured: * Plasma phenylalanine, tyrosine, and leucine concentration (expressed as mol/ L) Plasma enrichments (in MPE) of: o L-[1-13C]-phenylalanine o L-[D5]-phenylalanine o L-[1-13C]-tyrosine o L-[D4]-tyrosine o L-[D2]-tyrosine o L-[1-13C]-leucine o L-[1-13C]-alpha-KIC Other study parameters include plasma glucose and insulin concentrations, age, body weight, body length, BMI, body composition, blood pressure, and leg volume.	—

Measure

Time frame

Secondary endpoints include protein digestion and amino acid absorption kinetics and whole-body protein synthesis, breakdown, oxidation, and net balance. Therefore, the following parameters will be measured: * Plasma phenylalanine, tyrosine, and leucine concentration (expressed as *mol/ L) * Plasma enrichments (in MPE) of: o L-[1-13C]-phenylalanine o L-[D5]-phenylalanine o L-[1-13C]-tyrosine o L-[D4]-tyrosine o L-[D2]-tyrosine o L-[1-13C]-leucine o L-[1-13C]-alpha-KIC Other study parameters include plasma glucose and insulin concentrations, age, body weight, body length, BMI, body composition, blood pressure, and leg volume.

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)